Tjomsland Vegard, Aasrum Monica, Christoffersen Thoralf, Gladhaug Ivar P
Department of Pharmacology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Hepato-Pancreato-Biliary Surgery, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Oncotarget. 2017 May 11;8(42):71672-71684. doi: 10.18632/oncotarget.17800. eCollection 2017 Sep 22.
The pancreatic stellate cell (PSC) is the principal cell type of the desmoplastic stroma of pancreatic ductal adenocarcinoma (PDAC). PSCs interact with cancer cells and influence the progression of the disease through a complex network of signaling molecules including hepatocyte growth factor (HGF). Functional heterogeneity of PSCs within a tumor might conceivably influence tumor progression. We investigated PSC populations isolated from different human PDACs and examined the effects of PSC-conditioned medium on BxPC-3 and AsPC-1 pancreatic cancer cells. The different PSC populations exhibited a wide range of variation (120-3,000 pg/ml) in their ability to secrete HGF. Media from high-HGF-producing PSCs stimulated phosphorylation of Met, Gab1, and ERK in the cancer cells and induced increases in DNA synthesis and migration which were blocked by the Met inhibitor SU11274, indicating a role of HGF as a mediator. HGF levels produced by PSCs and the effects of PSC media on the cancer cells were increased by IL-1α and inhibited by TGFβ. The functional heterogeneity of PSCs in terms of HGF-mediated tumor-stroma interactions suggests that inhibition of the HGF pathway as a novel treatment approach in PDAC might have different effects in different subsets of patients.
胰腺星状细胞(PSC)是胰腺导管腺癌(PDAC)促纤维增生性基质的主要细胞类型。PSC与癌细胞相互作用,并通过包括肝细胞生长因子(HGF)在内的复杂信号分子网络影响疾病进展。肿瘤内PSC的功能异质性可能会影响肿瘤进展。我们研究了从不同人类PDAC中分离出的PSC群体,并检测了PSC条件培养基对BxPC-3和AsPC-1胰腺癌细胞的影响。不同的PSC群体在分泌HGF的能力上表现出广泛的差异(120 - 3000 pg/ml)。来自高HGF分泌型PSC的培养基刺激癌细胞中Met、Gab1和ERK的磷酸化,并诱导DNA合成和迁移增加,而Met抑制剂SU11274可阻断这些作用,表明HGF作为一种介质发挥作用。IL-1α可增加PSC产生的HGF水平以及PSC培养基对癌细胞的影响,而TGFβ则起抑制作用。PSC在HGF介导的肿瘤-基质相互作用方面的功能异质性表明,抑制HGF通路作为PDAC的一种新型治疗方法,可能对不同亚组的患者产生不同的效果。